In ALS motor neurons, chronic ISR activation via eIF2α phosphorylation creates a pathological state that represses axonal protein synthesis below the threshold needed for synaptic maintenance. Analogously, in Parkinson's disease, α-synuclein aggregation, mitochondrial dysfunction, and ER stress may chronically activate PERK/GCN2/PKR, driving eIF2α~P that suppresses axonal translation in nigrostriatal dopaminergic neurons. This ISR overflow could repress synthesis of synaptic proteins required for dopaminergic nerve terminal maintenance, contributing to progressive striatal denervation. The prediction is that reducing eIF2α~P will enhance axonal protein synthesis and attenuate axon terminal loss in PD models.

Analogy rationale: Both ALS motor neurons and PD dopaminergic neurons experience proteostatic stress from aggregating proteins and oxidative stress, which are known ISR activators, suggesting convergent ISR pathology across these neurodegenerative conditions.

In ALS motor neurons, chronic ISR activation via eIF2α phosphorylation creates a pathological state that represses axonal protein synthesis below the threshold needed for synaptic maintenance. Analogously, in Parkinson's disease, α-synuclein aggregation, mitochondrial dysfunction, and ER stress may chronically activate PERK/GCN2/PKR, driving eIF2α~P that suppresses axonal translation in nigrostriatal dopaminergic neurons. This ISR overflow could repress synthesis of synaptic proteins required for dopaminergic nerve terminal maintenance, contributing to progressive striatal denervation. The prediction is that reducing eIF2α~P will enhance axonal protein synthesis and attenuate axon terminal loss in PD models.

Analogy rationale: Both ALS motor neurons and PD dopaminergic neurons experience proteostatic stress from aggregating proteins and oxidative stress, which are known ISR activators, suggesting convergent ISR pathology across these neurodegenerative conditions.

Disanalogies: Motor neurons form large NMJs with peripheral axons, whereas nigrostriatal dopaminergic neurons have extensive unmyelinated axonal arbors in the striatum with distinct terminal structures; also, PD involves glial contributions and neuroinflammation not emphasized in the ALS ISR model.

Falsifiable prediction: Pharmacological inhibition of PERK (e.g., GSK2658157) or direct reduction of eIF2α~P in iPSC-derived dopaminergic neurons from GBA or LRRK2 PD patients will increase axonal synthesis of tyrosine hydroxylase and VMAT2, and preserve striatal axon terminal density in humanized mouse models.
This hypothesis was generated from `h-alsmnd-870c6115d68c` in `ALS` — judge it on its own merits but acknowledge the source.